DURECT Shares Soar After FDA Nod For Post-Surgical Pain Medication Posimir

by Vandana Singh, Benzinga Editor

February 2, 2021 9:43 AM | 1 min read |

The FDA has granted approval to DURECT Corporation's (NASDAQ: DRRX) POSIMIR (bupivacaine solution), a non-opioid, sustained-release local analgesic for the treatment of post-surgical pain following arthroscopic subacromial decompression surgery (a type of shoulder surgery), for up to 72 hours.
POSIMIR (bupivacaine solution) for infiltration use combines 660 mg of bupivacaine base with the SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. At the end of the surgery, POSIMIR is administered into the subacromial space under direct arthroscopic visualization.
The Company's management team will host a conference call today at 4:30 pm ET.
Price Action: DRRX shares gained 24.8% at $2.62 on the last check Tuesday.

Posted In: Biotech News Penny Stocks Small Cap FDA General FDA Approval

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.